Kiniksa Pharmaceuticals International (KNSA) Current Leases (2019 - 2026)

Kiniksa Pharmaceuticals International's Current Leases history runs 8 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• Quarterly Current Leases rose 38.31% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 38.31% YoY) and the FY2025 annual result came in at $3.0 million, up 49.87% from the prior year.
• Current Leases was $3.2 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $3.0 million in the prior quarter.
• Across five years, Current Leases topped out at $3.5 million in Q1 2023 and bottomed at $2.0 million in Q4 2024.
• A 5-year average of $2.7 million and a median of $2.5 million in 2025 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases slumped 34.55% — and 2025, when it soared 49.87%.
• Kiniksa Pharmaceuticals International's Current Leases stood at $3.3 million in 2022, then plunged by 31.75% to $2.3 million in 2023, then dropped by 11.54% to $2.0 million in 2024, then jumped by 49.87% to $3.0 million in 2025, then climbed by 6.13% to $3.2 million in 2026.
• Business Quant data shows KNSA's Current Leases at $3.2 million in Q1 2026, $3.0 million in Q4 2025, and $2.7 million in Q3 2025.